Mineralys Therapeutics Inc (MLYS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 09-2025 | 06-2025 | 03-2025 | 12-2024 | 09-2024 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -122,417 | -85,485 | -42,211 | -177,810 | -128,864 |
| Depreciation Amortization | 46 | 31 | 15 | 43 | 28 |
| Accounts receivable | 15 | 5 | 52 | 424 | 326 |
| Other Working Capital | 9,475 | 4,875 | -5,890 | 9,522 | 29,231 |
| Other Operating Activity | 8,353 | 4,918 | 2,547 | 1,507 | -192 |
| Operating Cash Flow | $-104,528 | $-75,656 | $-45,487 | $-166,314 | $-99,471 |
| Cash Flows From Investing Activities | |||||
| Change In Deposits | -286,264 | -135,757 | -92,876 | 115,055 | 31,485 |
| PPE Investments | N/A | N/A | N/A | -96 | -96 |
| Investing Cash Flow | $-286,264 | $-135,757 | $-92,876 | $114,959 | $31,389 |
| Cash Flows From Financing Activities | |||||
| Common Stock Issued | 494,242 | 199,025 | 189,289 | 116,356 | 116,302 |
| Other Financing Activity | 56 | 85 | -10 | -214 | -250 |
| Financing Cash Flow | $494,298 | $199,110 | $189,279 | $116,142 | $116,052 |
| Beginning Cash Position | 114,091 | 114,091 | 114,091 | 49,304 | 49,304 |
| End Cash Position | 217,597 | 101,788 | 165,007 | 114,091 | 97,274 |
| Net Cash Flow | $103,506 | $-12,303 | $50,916 | $64,787 | $47,970 |
| Free Cash Flow | |||||
| Operating Cash Flow | -104,528 | -75,656 | -45,487 | -166,314 | -99,471 |
| Capital Expenditure | N/A | 0 | 0 | -96 | -96 |
| Free Cash Flow | -104,528 | -75,656 | -45,487 | -166,410 | -99,567 |